KalVista Pharmaceuticals, Inc.

NASDAQ•KALV

CEO: Mr. Benjamin L. Palleiko

セクター: Healthcare

業種: Biotechnology

上場日: 2015-04-09

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

連絡先情報

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, 02142, United States

857-999-0075

www.kalvista.com

時価総額

$856.25M

PER (TTM)

-4.3

17.9

配当利回り

52週高値

$19.00

52週安値

$9.24

52週レンジ

79%

順位49Top 66.7%

3.2

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 3.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q2 2026 データ

売上高

$13.69M+0.00%

直近4四半期の推移

EPS

-$0.92+1.10%

直近4四半期の推移

フリーCF

-$32.71M-17.72%

直近4四半期の推移

2026 Q2 決算ハイライト

主なハイライト

EKTERLY Product Revenue Achieved Net product revenue reached $13.7M USD for the three/nine months ended September 30, 2025, following US launch.

Strong Cash Position Growth Cash, equivalents, restricted cash totaled $244.3M USD, marking a 799% increase from December 31, 2024.

Major Regulatory Milestones Met EKTERLY received FDA approval July 2025, followed by EU and Swiss regulatory authorizations in September 2025.

New Debt Issuance Secured Secured $139.4M USD proceeds from convertible notes issuance in September 2025 to fund operations and commercialization.

リスク要因

Operating Loss Widened Nine months operating loss increased 16% to $(154.7M)$ USD, driven by initial commercialization expenses and costs.

SG&A Expenses Surged Selling, General, Administrative expenses rose 98% to $126.0M USD for nine months, supporting EKTERLY launch activities.

Net Loss Increased Significantly Net loss for nine months grew 30% to $(158.9M)$ USD, reflecting ongoing development and launch expenditures.

Increased Operating Cash Use Cash used in operating activities rose 39% to $(127.0M)$ USD for nine months, indicating higher burn rate.

見通し

EKTERLY Commercial Expansion Anticipate continued operating losses supporting global EKTERLY commercialization and expansion into Switzerland pending reimbursement.

Pipeline Development Continues Development activities ongoing for pediatric EKTERLY expansion and preclinical research for oral Factor XIIa inhibitor program.

Sufficient Funding Runway Current capital resources expected to fund operations for at least the next twelve months from report issuance date.

Fiscal Year Change Implemented Fiscal year end changing from April 30 to December 31, effective December 31, 2025, creating transition period.

同業比較

売上高 (TTM)

RIGL

$294.28M

+64.1%

RGNX

$170.44M

+104.5%

ADCT

$81.36M

+14.9%

粗利益率 (最新四半期)

BCYC

100.0%

+1705.8pp

GOSS

100.0%

+0.0pp

ABSI

100.0%

+197.2pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
KOD	$1.23B	-5.6	-246.2%	28.5%
OLMA	$1.16B	-8.4	-41.5%	1.3%
SVRA	$1.07B	-9.8	-84.0%	11.8%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月24日

EPS:-$0.53

売上高:$32.29M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし